For this use, doctors may prescribe Baqsimi to adults as well as children 4 years and older. Both type 1 and type 2 diabetes are long-term conditions. If you and your doctor agree that Baqsimi is safe ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

It isn’t known whether Baqsimi (glucagon) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether ...

Baqsimi (glucagon) is a prescription drug that’s used to treat severely low blood sugar levels. The drug comes as nasal powder. It’s usually given as a one-time dose. Baqsimi is used in adults and ...

Eli Lilly announced Monday morning that it is divesting Baqsimi, its low blood sugar rescue treatment, to Amphastar Pharmaceuticals for $500 million. The boards of directors at both companies have ...

The Food and Drug Administration (FDA) has approved Baqsimi (glucagon; Eli Lilly) nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged 4 years and older. The Food and ...

Lilly focused on delivering the Company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit ...

(RTTNews) - Pharma major Eli Lilly and Company (LLY) said on Monday that it has inked a deal with Amphastar Pharmaceuticals, Inc. (AMPH), to divest BAQSIMI, the dry nasal spray to treat very low blood ...

Eli Lilly offloads innovative hypoglycemia nasal spray, Baqsimi, to Amphastar Pharmaceuticals bolstering Amphastar's diabetes portfolio. Eli Lilly has announced plans to sell Baqsimi, its innovative ...

Amphastar Pharmaceuticals remains a Hold as flat growth, margin pressure, and increased marketing spend cloud its outlook. AMPH's revenue is propped up by BAQSIMI and PRIMATENE, while legacy generics ...